Pakistan reports the first “confirmed” case of the BF.7 COVID-19 variant.
web desk
According to sources in the health department, Pakistan reported its first "confirmed" case of a new BF.7 Omicron coronavirus variant on Tuesday.
According to well-placed sources, the first case of the highly infectious COVID-19 strain, which has ravaged China, was found in the Gulshan-e-Iqbal area of Karachi.
Gene-sequencing has revealed the new coronavirus variant in a patient. The patient has never traveled to China before. According to the sources, the virus-infected individual began to exhibit symptoms after another individual met him at his office.
Fever, sore throat, runny nose, fatigue, vomiting, and diarrhea are the symptoms of the new COVID -19 variant.
The immune-evasive nature of BF.7 and the concerning indications of its expansion in China appear to be holding steady elsewhere, despite these characteristics.
It was estimated to be responsible for 5.7% of infections in the United States up until December 10, 2022, down from 6.6% the week before. The high reproduction rate of BF.7 and the Chinese situation may be partially attributable to China's low immunity to the previous infection and, possibly, vaccination.
The most recent data indicate that BF.7 transmits faster than other variants. It has a shorter incubation period and a greater capacity to infect individuals who have been vaccinated against COVID-19.
According to sources in the health department, Pakistan reported its first “confirmed” case of a new BF.7 Omicron coronavirus variant on Tuesday.
According to well-placed sources, the first case of the highly infectious COVID-19 strain, which has ravaged China, was found in the Gulshan-e-Iqbal area of Karachi.
Gene-sequencing has revealed the new coronavirus variant in a patient. The patient has never traveled to China before. According to the sources, the virus-infected individual began to exhibit symptoms after another individual met him at his office.
Fever, sore throat, runny nose, fatigue, vomiting, and diarrhea are the symptoms of the new COVID -19 variant.
The immune-evasive nature of BF.7 and the concerning indications of its expansion in China appear to be holding steady elsewhere, despite these characteristics.
It was estimated to be responsible for 5.7% of infections in the United States up until December 10, 2022, down from 6.6% the week before. The high reproduction rate of BF.7 and the Chinese situation may be partially attributable to China’s low immunity to the previous infection and, possibly, vaccination.
The most recent data indicate that BF.7 transmits faster than other variants. It has a shorter incubation period and a greater capacity to infect individuals who have been vaccinated against COVID-19.
